OncoMatch/Melanoma/PD-L1 (CD274)
MelanomaPD-L1 (CD274) Clinical Trials
PD-L1 expression correlates with but does not strictly predict checkpoint immunotherapy response in melanoma; pembrolizumab and nivolumab are approved regardless of PD-L1 status, though PD-L1-high tumors may have higher response rates to monotherapy. Nivolumab plus ipilimumab shows superior PFS/OS over monotherapy across PD-L1 subgroups. Trials explore PD-L1 as a predictive marker for monotherapy vs. combination checkpoint selection, and novel IO combinations in PD-L1-stratified cohorts.
Top recruiting PD-L1 (CD274) Melanoma trials
Ranked by phase and US site count. See all 13 trials matched to your profile →
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
mAbxience Research S.L.
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad, Inc.
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme LLC
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca